Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 864 > Lecture 14 - Colorectal Cancer > Flashcards

Lecture 14 - Colorectal Cancer Flashcards

1
Q

Colorectal is ____ most common in incidence and death rates

A

3rd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Epidemiology

A

incidence is increased in industrialized nations with males having slightly increased incidence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk factors

A

age - increases starting after age 40 and is greater after 50 years of age; family history of colon cancer
dietary factors: high fat, low fiber, reduced folate, reduced calcium; polyps; smoking, alcohol, obesity; ulcerative colitis or crohn’s disease (chronic inflammation)
hereditary syndromes: familial adenomatous polyposis (FAP), autosomal dominant disorder, mutation of adenomatous polyposis coli gene on chromosome 5, hereditary nonpolyposis colorectal cancer
development of 100’s-1000’s of adenomatous polyps (nearly 100% lifetime risk of developing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pathophysiology

A

malignant polyps tend to grow from inner basement membrane of bowel wall outward into mucosa, submucosa, muscularis, and serosa
metastatic spread via lymphatic and hematogenous routes to lymph nodes, lungs, liver, and bone
>95% are adenocarcinomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Presentation

A

may be asymptomatic; rectal bleeding, anemia, N/V, change in bowel habits
some present with metastatic disease: jaundice, hepatomegaly, weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Additional testing-work up

A

defective DNA mismatch repair (dMMR)
test for microsatellite instabilit (MSI) or test for loss of genes involved in DNA MMR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Early stage disease and MMR

A

dMMR or MSI-H tumor predicts decreased benefit from adjuvant 5-FU based therapy for stage II disease: chemo won’t work!!
stage III patients with dMMR or MSI-H disease can benefit from adjuvant 5-FU: chemo will be of benefit!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

All pts with colon cancer diagnosis should be tested for

A

mismatch repair or microsatellite instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment options

A

surgery: early stage disease
radiation therapy: well established for rectal cancer, but more controversial in colon cancer; can be used to alleviate pain and decrease bleeding
chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treatment goals for stage I,II, and III

A

considered potentially curable; achieve remission and avoid disease recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Treatment goals for stage IV

A

incurable/palliation
decrease sx and avoid disease related complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Localized therapy (stage I and II)

A

surgery alone is definitive therapy: partial or total colectomy + lymph nodes
no proven benefit with chemo in stage II; guidelines recommend against adjuvant chemo in stage II, can recommend if pt is high risk
if MSI-H or dMMR, then will NOT benefit from chemo in stage II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Stage II disease (chemo)

A

FOLFOX: reasonable for high risk or intermediate risk stage II pts - 5-FU, leucovorin, oxaliplatin
CapeOX also an option - capecitabine, oxaliplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Stage III disease

A

surgery including regional lymph node removal
chemo indicated for this stage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Stage III disease: chemotherapy

A

principles of adjuvant therapy: capecitabine appears to be = to bolus 5-FU/leucovorin in stage III pts
bevacizumab, cetuximab, panitumumab, and irinotecan DO NOT play a role in this setting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

FOLFOX

A

FOLFOX = 5-FU, oxaliplatin, leucovorin
decrease in recurrence, increased 5-year disease free survival
toxicities with oxaliplatin (paresthesia, neutropenia, GI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Adjuvant chemo options

A

mFOLFOX6: oxaliplatin, leucovorin, 5-F; pts take chemo pump home
CapeOX: oxaliplatin, capecitabine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Current recommendations by NCCN

A

low risk: CapeOX for 3 mo or FOLFOX for 3-6 mo
high risk: CapeOX for 3-6 mo or FOLFOX for 6 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

IDEA trial conclusions

A

risk-based approach
with CapeOX: 3 mo as effective as 6 mo, especially in low-risk pts
with FOLFOX: 6 mo was more effective than 3 mo, especially in high risk pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How to implement in practice: stage III colon cancer

A

low risk: CapeOX for 3 mo
high risk: FOLFOX for 6 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

FOLFOX and CapeOX considerations

A

FOLFOX: requires port, 2-day pump, more infusions overall, increased myelosuppression and mouth sores; repeated every 2 weeks
CapeOX: port not required (oral agent), less infusions overall (not continuous), increased hand foot syndrome and diarrhea; capecitabine requires renal dose adjustments, adherence, copay, look into drug/drug interactions; repeat every 3 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Metastatic disease colon cancer

A

chemo is mainstay of therapy
survival has increased from 12 mo with 5-FU monotherapy to ~2 years with the addition of irinotecan, oxaliplatin, and newer biologics
surgery could play a role in isolated disease
radiation therapy for palliation of sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Which chemo regimen to use for mestatic disease

A

pt performance status
co-morbidities that determine therapy: neuropathy, UGT1A1 deficiency

24
Q

Advanced disease and MMR

A

predict benefit to PD-L1 inhibitors: pembrolizumab and nivolumab shown benefit in metastatic setting, both approved for pts unresectable or metastatic, with dMMR or MSI-H tumors after FOLFOX and FOLFIRI

25
Q

Predictive biomarkers: K-RAS

A

mutations predict lack of response to anti-EGFR monoclonal antibodies
cetuximab and panitumumab: DO NOT use if have KRAS mutation

26
Q

Predictive biomarkers: BRAF

A

5-15% of pts will have this mutation

27
Q

1st line metastatic disease chemo regimens: no targetable mutations

A

mFOLFOX6 +/- bevacizumab
CapeOX +/- bevacizumab
FOLFIRI +/- bevacizumab
FOLFIRINOX +/- bevacizumab

28
Q

1st line metastatic disease chemo regimens: KRAS

A

FOLFOX or CapeOX + cetuximab or panitumumab OR FOLFIRI + cetuximab or panitumumab

29
Q

1st line metastatic disease chemo regimens: dMMR/MSI-H

A

nivolumab + ipilimumab or pembrolizumab

30
Q

1st line metastatic disease chemo regimens: HER2 +

A

trastuzumab + pertuzumab or lapatinib OR fam-trastuzumab deruxtecan-nxki

31
Q

Metastatic chemo options

A

FOLFOX, CapeOX, FOLFIRI, bevacizumab, cetuximab, FOLFIRINOX

32
Q

1st line metastatic disease if someone cannot tolerate intensive chemo: no targetable mutations

A

5-FU + leucovorin OR capeticabine +/- bevacizumab

33
Q

1st line metastatic disease if someone cannot tolerate intensive chemo: KRAS

A

cetixumab OR panitumumab

34
Q

1st line metastatic disease if someone cannot tolerate intensive chemo: dMMR/MSI-H

A

nivolumab +/- ipilumumab OR pembrolizumab

35
Q

1st line metastatic disease if someone cannot tolerate intensive chemo: HER2 +

A

trastuzumab + pertuzumab or lapatinib or tucatinib

36
Q

Second line therapy for metastatic disease

A

if prior oxaliplatin based regimens: use FOLFIRI
if prior irinotecan-based regimens: use FOLFOX

37
Q

Colon cancer screening tests

A
  1. primarily detect cancer: fecal occult blood test (FOBT) and fecal immunohistochemical test (FIT), or FIT DNA
  2. detect cancer and advanced lesions: endoscopic and radiologic exams
38
Q

Test to primarily detect colon cancer: Fecal occult blood testing

A

high false-negative rate, decreased mortality by 1/3rd
has increased sensitivity/specificity
to avoid false positives: avoid red meat and raw veggies with peroxidase activity
to avoid false negatives: avoid vit C

39
Q

Test to primarily detect colon cancer: Fecal immunochemical test (FIT)

A

detects hemoglobin and is more specific than guaiac based tests
not subject to false negative rates like FOBT
FIT DNA: detects hemoglobin along with certain DNA biomarkers

40
Q

Test to primarily detect cancer and advanced lesions: endoscopy

A

flexible sigmoidoscopy: examines lower 60% of bowel
colonoscopy: examines enture bowel and can remove premalignant lesions during procedure

41
Q

Colon cancer screening guidelines applies to

A

men and women >/= 45 yrs old

42
Q

ACS screening guidelines

A

avg risk: annual FOBT or annual FIT or multi-target stool DNA test every 3 yrs OR flexible sigmoidoscopy every 5 years or colonoscopy every 10 yrs or CT colonography every 5 yrs

43
Q

ACS screening guidelines: family history

A

begin annual screening at 40
1st degree relative with colon cancer

44
Q

ACS screening guidelines: HNPCC

A

begin annual screening at 20-25

45
Q

ACS screening guidelines: FAP

A

being annual screening at 10-12

46
Q

Colon cancer prevention - diet

A

diet: high fiber, low fat, (decrease fecal bile acids) diet high in antioxidant rich fruits and veggies
calcium rich diet decreases proliferative response to fatty/bile acids

47
Q

Colon cancer prevention - cyclooxegenase inhibitors

A

celecoxib - decreases the number of adenomatous colorectal polyps in familial adenomatous polypsosis (FAP)
NSAIDS or aspirin
colectomy

48
Q

5-fluorouracil

A

converted to FUTP and FdUMP; FUTP incorporates into RNA and impairs protein synthesis; FdUMP binds thymidylate synthase and reduces rate of DNA synthesis, replication, and repair
extensively metabolized by dihydropyrimidine dehydrogenase (DPD) in liver - pts with DPD deficiency have exaggerated 5-FU toxicities - diarrhea, mucositis, myelosuppression

49
Q

Leucovorin

A

synergizer with 5-FU
stablizes the binding of FdUMP to TS resulting in enhancement of toxicity of FdUMP

50
Q

Irinotecan

A

big SE: diarrhea and neutropenia
pro-drug of SN-38, inhibits topoisomerase I
early onset diarrhea (cholinergic syndrome) - give atropine
late onset diarrhea - give loperamide
UGT1A1 deficiency prevents SN-38 conversion and increased toxicity

51
Q

Oxaliplatin

A

platinum compound, cross-links DNA, inhibiting DNA replication
inactive as single agent, given with 5-FU and leucovorin to make FOLFOX
toxicities: neuopathy, cold intolerances, sensation of not being able to breathe

52
Q

Capecitabine

A

oral pro-drug of 5-FU
dose limiting toxicity is hand-foot syndrome and diarrhea

53
Q

Cetuximab

A

do NOT use if KRAS mutation!; only used in KRAS wild type pts
monoclonal antibody, binds to extracellular domain of EGFR
AEs: acneform rash and hypomagnesemia; premedicate with H1 antagonist

54
Q

Panitumumab

A

recombinant human IgG2 monoclonal antibody that binds to EGFR
AEs: acenform rash and hypomagnesemia

55
Q

Bevacizumab

A

VEGF inhibitor: monoclonal antibody that binds VEGF potentially decreasing angiogenesis (new blood vessel formation)
given in combo with 5-FU, leucovorin, and irinotecan
significant toxicity: bleeding, HTN, proteinuria, thromboembolism, GI perforations, decreased wound healing
many black box warnings

PHRM 864 (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions